Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma

Investigational New Drugs

Volumn 16, Issue 2, 1998, Pages 175-177

  Ajani, Jaffer A ^a   Pazdur, Richard ^a   Dumas, Pamela ^a   Fairweather, Jackie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Colorectal carcinoma; Taxol

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS CATHETER; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; LIVER FUNCTION; MALE; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PACLITAXEL;

EID: 0031730104     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006093008179     Document Type: Article

References (17)

1. Parker SL, Tong T, Boldan, Wingo PA: Cancer statistics 1997. Ca Cancer J Clin 47: 5-27, 1997
2. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 330: 1136-1142, 1994
3. Leichman CG, Fleming TR, Muggia FM et al.: Phase II study of 5-fluorouracil and its modulation in advanced colorectal cancer: a Southwestern Oncology Group Study. J Clin Oncol 13: 1303-1311, 1995
4. Poon MA, O'Connell MJ, Moertel CG et al.: Biochemical modulation of fluorouracil evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407-1418, 1988
5. Shimada Y, Rougier P, Pitot H: Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer 32A: S13-17, 1996
6. Rothenberg ML: The current status of irinotecan (CPT- 11) in the United States. Ann NY Acad Sci 803: 272-281, 1996
7. Wani MC, Taylor HL, Wall ME et al.: Plant antitumor agents VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from taxus brevifolia. Am Chem Soc 893: 2325-2327, 1971
8. Parness J, Horwitz SB: Taxol binds to polymerized microtubules in vitro. J Cell Biol 91: 479-487, 1981
9. Schiff PB, Horwitz SB: Taxol assembles tubulin in the absence of exogenous guanosine 5′triphosphate or microtubule-associated protein. Biochemistry 20: 3247-3252, 1981
10. Kumar N: Taxol-induced polymerization of purified tubulin. Mechanism of Action. J Biol Chem 256: 10435-10441, 1981
11. Rowinsky EK, Donehower RC, Jones RJ et al.: Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 48: 4093-4100, 1988
12. Spriggs DR, Tondini C: Taxol administered as a 120-hour infusion. Invest New Drugs 10: 275-278, 1992
13. Wilson WH, Chabner BA, Bryant G et al.: Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 13: 381-386, 1995
14. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH: Comprehensive criteria for therapy-induced toxicity. Cancer Invest 8: 141-153, 1990
15. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). New Engl J Med 332: 1004-1014, 195
16. National Cancer Institute Clinical Brochure: Taxol (NSC 125973). Division of Cancer Treatment, NCI, Bethesda, MD, September, 1983, pp 6-12
17. Pazdur R, Lassere Y, Soh LT et al.: Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncology 5: 468-470, 1994